Wellington Management Group LLP Cuts Stock Position in Sanofi (NASDAQ:SNY)

Wellington Management Group LLP lessened its stake in Sanofi (NASDAQ:SNY - Free Report) by 2.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,650,334 shares of the company's stock after selling 132,206 shares during the period. Wellington Management Group LLP owned about 0.18% of Sanofi worth $267,999,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Stablepoint Partners LLC grew its holdings in shares of Sanofi by 0.8% in the third quarter. Stablepoint Partners LLC now owns 23,893 shares of the company's stock worth $1,377,000 after purchasing an additional 189 shares during the last quarter. PDS Planning Inc boosted its position in Sanofi by 3.1% during the 3rd quarter. PDS Planning Inc now owns 6,643 shares of the company's stock valued at $383,000 after buying an additional 200 shares during the period. Eagle Ridge Investment Management grew its holdings in Sanofi by 3.8% in the 3rd quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company's stock worth $321,000 after acquiring an additional 203 shares during the last quarter. Financial Advocates Investment Management raised its stake in shares of Sanofi by 3.4% during the third quarter. Financial Advocates Investment Management now owns 6,327 shares of the company's stock valued at $365,000 after acquiring an additional 206 shares during the last quarter. Finally, Angeles Investment Advisors LLC raised its stake in shares of Sanofi by 1.9% during the third quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company's stock valued at $653,000 after acquiring an additional 210 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

SNY has been the topic of a number of research analyst reports. Citigroup upgraded Sanofi to a "strong-buy" rating in a report on Tuesday, September 17th. StockNews.com lowered Sanofi from a "buy" rating to a "hold" rating in a research report on Friday. Two analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $57.50.

Sanofi Trading Down 0.1 %

Shares of NASDAQ SNY traded down $0.05 during midday trading on Friday, hitting $48.46. 1,590,336 shares of the company traded hands, compared to its average volume of 2,300,876. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The firm has a market cap of $122.98 billion, a P/E ratio of 24.72, a P/E/G ratio of 1.22 and a beta of 0.58. The stock has a 50-day moving average price of $51.90 and a 200 day moving average price of $52.11. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $0.22 by $1.35. The business had revenue of $13.44 billion for the quarter, compared to analysts' expectations of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business's revenue was up 12.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.55 EPS. As a group, analysts expect that Sanofi will post 4.28 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.